Gemtuzumab ozogamicin: time to resurrect?
J. Clin. Oncol., Nov;30(32):3921-3 (2012)
Intensity of conditioning for allogeneic haemopoetic cell transplantation.
Lancet Oncol., Oct;13(10):966-8 (2012)
Management of acute promyelocytic leukemia: implications for treatment of other cancers.
Oncology (Williston Park, N.Y.)., Jul;26(7):641, 646-7 (2012)
Acute myeloid leukemia with normal cytogenetics.
Curr Oncol Rep., Oct;14(5):359-68 (2012)
Retrospective comparison of clofarabine versus fludarabine in combination with high dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
Haematologica., Jul (2012)
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Haematologica., Nov;97(11):1736-42 (2012)
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia.
Haematologica., Sep;97(9):1401-4 (2012)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.
Blood., Jun;119(26):6198-208 (2012)
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
Biol. Blood Marrow Transplant., Aug;18(8):1211-8 (2012)
Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.
Am. J. Hematol., Jan;87(1):89-99 (2012)
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.
Haematologica., May;97(5):739-42 (2012)
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
J. Clin. Oncol., Nov;29(33):4417-23 (2011)
Impact of residual normal metaphases in core binding factor acute myeloid leukemia.
Cancer., May;118(9):2420-3 (2012)
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
Br. J. Haematol., Oct;155(2):182-9 (2011)
Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
J. Clin. Oncol., Jul;29(20):2743-6 (2011)
Treatment of acute myeloid leukemia in the elderly.
Haematologica., Jun;96(6):795-8 (2011)
Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.
Haematologica., Jun;96(6):914-7 (2011)
Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype.
Haematologica., Apr;96(4):631-2 (2011)
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
J. Clin. Oncol., Mar;29(9):1190-7 (2011)
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.
Blood., Oct;116(14):2420-8 (2010)